Over 100 patients successfully treated with the DurAVR ® THV, including de novo (first time) aortic stenosis cases, valve-in-valve (ViV) patients and complex anatomies such as bicuspid aortic ...

Anteris Chief Medical Officer, Chris Meduri, M.D., commented: “The one-year data for DurAVR ® THV continues to validate its groundbreaking hemodynamic performance, demonstrating sustained ...